Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01702285 · ClinicalTrials.gov registry record · Phase 1
Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients
A Phase 1 study, sponsored by Curis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01702285 is a Phase 1 study that was terminated before completion, run by Curis. The registered enrollment target is 3 participants.
The verdict
NCT01702285, a Phase 1 study, was terminated before completion, sponsored by Curis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the safety and tolerability of orally administered CUDC-101 in cancer patients, and to determine a dose for further testing. This study will also determine how well CUDC-101 is absorbed into the blood after being given orally, assess CUDC-101 blood levels and what happens to the study drug in the body, and study how the body reacts to the study drug and what effects it has on tumors. CUDC-101 has been administered to cancer patients as an intravenous (IV) infusion in other research studies, but has not been studied when given orally.
Interventions
- DRUG CUDC-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-09 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01702285
The ClinicalTrials.gov registry entry for NCT01702285 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Curis, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CUDC-101 is the first listed.
NCT01702285 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01702285 about?
NCT01702285 is a clinical study titled "Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients". The main purpose of this study is to determine the safety and tolerability of orally administered CUDC-101 in cancer patients, and to determine a dose for further testing. This study will also determine how well CUDC-101 is absorbed into the blood after being given orally, assess CUDC-101 blood leve...
What is the current status of trial NCT01702285?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2012-09. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01702285?
The interventions under investigation include: CUDC-101 (DRUG).
Who is sponsoring clinical trial NCT01702285?
This trial is sponsored by Curis, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.